Category: Cytokine Storm

IL-13 decreases susceptibility to airway epithelial SARS-CoV-2 infection but increases disease severity in vivo

Posted on | Posted on John Murphy | Leave a Comment on IL-13 decreases susceptibility to airway epithelial SARS-CoV-2 infection but increases disease severity in vivo

Shreya Ghimire, Biyun Xue, Kun Li, Ryan M Gannon, et. al.doi: https://doi.org/10.1101/2024.07.03.60194 Abstract Treatments available to prevent progression of virus-induced lung diseases, including coronavirus disease 2019 (COVID-19) are of limited benefit once respiratory failure occurs. The efficacy of approved and emerging cytokine signaling-modulating antibodies is variable and is affected by disease course and patient-specific inflammation patterns. Therefore, understanding the role of inflammation on the […]

The knowns and unknowns of long COVID-19: from mechanisms to therapeutical approaches

Posted on | Posted on John Murphy | Leave a Comment on The knowns and unknowns of long COVID-19: from mechanisms to therapeutical approaches

Roxana Gheorghita1,2Iuliana Soldanescu3Andrei Lobiuc2 , et. al., Front. Immunol., 03 March 2024, Sec. Viral Immunology, Volume 15 – 2024 | https://doi.org/10.3389/fimmu.2024.1344086 The coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has been defined as the greatest global health and socioeconomic crisis of modern times. While most people recover after being infected with the virus, a significant […]

Pathophysiological, immunological, and inflammatory features of long COVID

Posted on | Posted on John Murphy | Leave a Comment on Pathophysiological, immunological, and inflammatory features of long COVID

Karen Bohmwald1,2†Benjamín Diethelm-Varela1†Linmar Rodríguez-Guilarte1 , et. al., Front. Immunol., 27 February 2024, Sec. Viral Immunology, Volume 15 – 2024 | https://doi.org/10.3389/fimmu.2024.1341600 The COVID-19 pandemic continues to cause severe global disruption, resulting in significant excess mortality, overwhelming healthcare systems, and imposing substantial social and economic burdens on nations. While most of the attention and therapeutic efforts have […]

Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection

Posted on | Posted on John Murphy | Leave a Comment on Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection

Chansavath Phetsouphanh, Brendan Jacka, et. al., Nature Communications volume 15, Article number: 3315 (2024) Abstract This study investigates the humoral and cellular immune responses and health-related quality of life measures in individuals with mild to moderate long COVID (LC) compared to age and gender matched recovered COVID-19 controls (MC) over 24 months. LC participants show elevated nucleocapsid IgG levels at 3 months, […]

Are we treating long COVID wrong? Immune-boosting treatment takes new approach

Posted on | Posted on John Murphy | Leave a Comment on Are we treating long COVID wrong? Immune-boosting treatment takes new approach

Coronavirus data All data and statistics are based on publicly available data at the time of publication. Some information may be out of date. Visit our coronavirus hub for the most recent information on COVID-19. Was this helpful? A monoclonal antibody treatment called leronlimab could reduce long COVID symptoms in some patients, according to a recent pilot study published in the […]

Severe COVID-19 May Lead to Long-Term Innate Immune System Changes

Posted on | Posted on John Murphy | Leave a Comment on Severe COVID-19 May Lead to Long-Term Innate Immune System Changes

NIH-Funded Research Links Alterations to Inflammatory Protein, Underscores Vaccine Importance August 18, 2023 Severe COVID-19 may cause long-lasting alterations to the innate immune system, the first line of defense against pathogens, according to a small study funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. These changes […]

Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies

Posted on | Posted on John Murphy | Leave a Comment on Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies

Suo-wen Xu, Iqra Ilyas & Jian-ping Weng  Acta Pharmacologica Sinica volume 44, pages695–709 (2023) Cite this article 17 October 2022 Abstract The fight against coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is still raging. However, the pathophysiology of acute and post-acute manifestations of COVID-19 (long COVID-19) is understudied. Endothelial cells are sentinels lining the innermost layer of blood vessel that […]

COVID-19 can trigger auto-immune disorders-related antibodies, causing thrombosis and other complications

Posted on | Posted on John Murphy | Leave a Comment on COVID-19 can trigger auto-immune disorders-related antibodies, causing thrombosis and other complications

SEPTEMBER 12, 2023 by Maria Fernanda Ziegler, FAPESP Medical Express An article published in npj Aging reveals that natural production of auto-antibodies increases with age, and that infection by SARS-CoV-2 can exacerbate production of auto-antibodies relating to auto-immune diseases, helping to explain why aging increases the chances of developing severe COVID-19. The study also discovered some of the factors that […]

Detrimental effects of COVID-19 in the brain and therapeutic options for long COVID: The role of Epstein–Barr virus and the gut–brain axis

Posted on | Posted on John Murphy | Leave a Comment on Detrimental effects of COVID-19 in the brain and therapeutic options for long COVID: The role of Epstein–Barr virus and the gut–brain axis

Kenji Hashimoto, Molecular Psychiatry (2023) Published: 04 July 2023 Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in a serious public health burden worldwide. In addition to respiratory, heart, and gastrointestinal symptoms, patients infected with SARS-CoV-2 experience a number of persistent neurological and psychiatric symptoms, known as […]

Doxycycline, a widely used antibiotic in dermatology with a possible anti‐inflammatory action against IL‐6 in COVID‐19 outbreak

Posted on | Posted on John Murphy | Leave a Comment on Doxycycline, a widely used antibiotic in dermatology with a possible anti‐inflammatory action against IL‐6 in COVID‐19 outbreak

Claudio Conforti, 1 Roberta Giuffrida, 2 Iris Zalaudek, 1 and Nicola Di Meo 1 Dermatol Ther. 2020 Jul-Aug; 33(4): e13437. Published online 2020 May 15. doi: 10.1111/dth.13437 PMCID: PMC7235480PMID: 32314492 The recent SARS‐CoV‐2 pandemic, for which there is still no approved vaccine, required research into effective treatments to limit, contain, and improve the outcome of affected patients. 1 , 2 Symptoms of coronavirus disease 19 (COVID‐19) range from mild to severe […]